Back home
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Contact
Our projects

Limno Pharma, S.L.

New Drugs for ocular diseases

Visit Website

Description

Pharmaceutical company dedicated to the research and development of new drugs for the treatment of ophthalmic diseases, based on two exclusively licensed patents. We are specialized in retinal degeneration, diseases with high prevalence and scarce treatment. Our initial focus is on the treatment of two retinal degenerative diseases, retinitis pigmentosa (RP) and dry age-related macular degeneration (dry-AMD).

Our first product, LIM21, is a chemical derivative of a natural product which shows high efficacy decreasing the symptoms of RP and dry AMD in mouse models. The main competitive advantage of LIM21 over the only drug in the market, that are administered as intraocular injections, is the administration as eye drops.

Current needs

We are currently raising our series A, budgeted in 5M€, for performing CMC and preclinical regulatory experiments. This series A will be followed by a series B, budgeted in 7M€, for performing a clinical trial phase I/IIa with Retinitis Pigmentosa patients. In our business model, we plan to follow the development of the drugs until completion of the clinical trial, moment in which we will negotiate an acquisition or licensing deal with a pharma company.
Ophthalmological opportunities are currently very attractive for pharmaceutical companies, and recent deals closed in ophthalmology have been very profitable for investors.

Meet the team

Elena Puerta Fernández

CEO

Juan Carlos Morales

Co-founder and Scientific Advisor

Francisco Díaz

Co-founder and Scientific Advisor

Natalia Pérez

Co-founder

David Alcántara

Co-founder, administrator and CFO

Actuación del Campus de excelencia cofinanciadas por la Unión Europea a través del Fondo Europeo de Desarrollo Regional (FEDER) y la Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía.

Proyecto Singular ILIBERIS: Actuaciones Singulares de Transferencia de Conocimiento en el CEI BIOTIC.

Marco por el que se impulsa el desarrollo de Proyectos Singulares de actuaciones de transferencia en los Campus de Excelencia Internacional en las áreas de la Estrategia de Investigación e Innovación para la Especialización Inteligente de Andalucía (RIS3) con cargo al Programa Operativo FEDER 2014-2020 de Andalucía.